Stay updated on Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T20:22:15.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    1%
    Check dated 2025-02-10T09:31:53.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T06:16:01.000Z thumbnail image
  7. Check
    51 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-19T20:14:44.000Z thumbnail image
  8. Check
    58 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.
    Difference
    0.2%
    Check dated 2025-01-12T17:07:37.000Z thumbnail image
  9. Check
    66 days ago
    Change Detected
    Summary
    The latest update includes detailed definitions and assessments of Duration of Response (DOR), Progression-Free Survival (PFS), and Overall Survival (OS) for participants in the MK-3475-913 study, with a notable increase in the DOR reporting period from approximately 13 years to 58 months, while previous entries have been removed.
    Difference
    3%
    Check dated 2025-01-05T13:55:33.000Z thumbnail image

Stay in the know with updates to Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.